Advertisement
Survey Series
Institutions
For Advertisers
|
|
||||
|
Manufacturing on a Grand Scale
As more biotech drugs make it to market, the question becomes 'can they be made more cheaply?'
Email: Alison McCook - amccook@the-scientist.com The Scientist 2005, 19(3):34
|
||||
|
|
||||
|
Biotech drugs such as genetically engineered hormones and monoclonal antibodies make up a sizeable and growing proportion of the pharmaceutical market. Biologics represented 7% of the pharmaceutical market in 2002, and by 2006 they are expected to make up 12%. Seven hundred new biologics are currently being tested, with up to 200 entering late-stage trials. This year, as many as 40 new biologics could make it to the market, according to Kalorama Information, a life science market research firm in New York.[1]
|
For FREE access to this article and more, you must register.
|
|||||||||
|
